StockData

Ocugen vs Outlook Therapeutics

OCGN and OTLK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How OCGN and OTLK compare

Ocugen is the larger company, worth 2.9 times as much as Outlook Therapeutics ($257M against $87.8M).

Outlook Therapeutics scores higher on the StockData Score (4 against 1 for Ocugen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricOCGNOTLK
Size and price
Market cap$257M$87.8M
Share price$0.757$0.361
Change, 1 year−36.4%−77.0%
Change, 5 years−88.3%−98.7%
Beta (5Y)−0.163.72
Employees11617
StockData Score
Total score14 (better)
Valuation score00
Growth score1 (better)0
Performance score00
Health score04 (better)
Dividend score00
Valuation
FCF yield−23.8%–
Growth
Revenue growth, 5Y average152%–
Financial health
Interest coverage−8.2×–
Current ratio0.800.81 (better)
Altman Z-score−6.09 (better)−40.77
Piotroski F-score01 (better)
Dividends and buybacks
Buyback yield–−62.3%
Shareholder yield0.00% (better)−62.3%
Ownership
Held by institutions42.8%8.4%
Held by insiders2.4%28.5%
Insider net buying, 12 months−$1.1M$7.9M (better)
Short interest, % of float32.5%20.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.